Phoenix and Raven launch direct-to-patient generic semaglutide after Health Canada approval
Generic semaglutide is cheaper, but access is now the real battleground. Phoenix and Raven are testing Canada’s GLP-1 telehealth future.
Dr. Reddy’s moves first in Canada’s generic semaglutide market. Can access improve?
GLP-1 demand is booming, but access remains uneven. Dr. Reddy’s Canada launch tests whether generics can change semaglutide economics.
Why Apotex’s Apo-Semaglutide approval could reshape Canada’s diabetes drug market
Canada has generic Ozempic momentum. Apotex’s approval turns GLP-1 access into a pricing and supply-chain test.
Coya Therapeutics expands ALS trial into Canada as COYA 302 gains Health Canada clearance
Coya Therapeutics expands its ALS trial for COYA 302 to Canada after Health Canada clearance. Explore what this means for the biotech’s immunotherapy platform.
Spiderwort Biotechnologies’ cellulose scaffolds show promise in spinal cord repair
Spiderwort’s spinal cord scaffold earns scientific validation as its dermal filler enters human trials Spiderwort Biotechnologies Inc. has reported two key developments in its cellulose-based regenerative platform, signaling a step forward in both neurorepair and aesthetic medicine. A peer-reviewed study published in Scientific Reports confirms that the company’s plant-derived scaffolds promote neural tissue repair and […]